Arts & Entertainment

Playwright Explores Lebanon's Sectarian Dividei
X
July 17, 2013 5:17 PM
A country with 18 religious sects and a history of sectarian conflict, Lebanon often seems on the brink of violence. Since the uprising in Syria began more than two years ago, that tension has escalated, especially between Sunni and Shia. Lebanese playwright and director Yehia Jaber is trying to defuse the tension through theater. In a one-man play, he highlights the history of Tarik al Jadidah, a low income and predominantly Sunni neighborhood in Beirut that often is seen as a barometer of Sunni sentiment. Paige Kollock reports for VOA from Beirut that the play is one way of the many ways Lebanese are dealing with the tension in the country through art.

Playwright Explores Lebanon's Sectarian Divide

Published July 17, 2013

A country with 18 religious sects and a history of sectarian conflict, Lebanon often seems on the brink of violence. Since the uprising in Syria began more than two years ago, that tension has escalated, especially between Sunni and Shia. Lebanese playwright and director Yehia Jaber is trying to defuse the tension through theater. In a one-man play, he highlights the history of Tarik al Jadidah, a low income and predominantly Sunni neighborhood in Beirut that often is seen as a barometer of Sunni sentiment. Paige Kollock reports for VOA from Beirut that the play is one way of the many ways Lebanese are dealing with the tension in the country through art.


You May Like

US Imposes Sanctions on Alleged Honduran Drug Gang

Treasury department alleges Los Valles group is responsible for smuggling tens of thousands of kilograms of cocaine into US each month More

At 91, Marvel Creator Stan Lee Continues to Expand his Universe

Company's chief emeritus hopes to interest new generation of children in superheroes of all shapes and sizes by publishing content across multiple media platforms More

Photogallery New Drug Protects Against Virus in Ebola Family

Study by researchers at University of Texas Medical Branch, Tekmira Pharmaceuticals is first looking at drug's effectiveness after onset of symptoms More